Repurposing Anti-Cancer Drugs for COVID-19 Treatment.
COVID-19
anti-cancer drugs
drug-repurposing
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
09
2020
accepted:
29
10
2020
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
15
12
2020
Statut:
epublish
Résumé
The novel coronavirus disease 2019 (COVID-19) pandemic has caused catastrophic damage to human life across the globe along with social and financial hardships. According to the Johns Hopkins University Coronavirus Resource Center, more than 41.3 million people worldwide have been infected, and more than 1,133,000 people have died as of October 22, 2020. At present, there is no available vaccine and a scarcity of efficacious therapies. However, there is tremendous ongoing effort towards identifying effective drugs and developing novel vaccines. Early data from Adaptive COVID-19 Treatment Trials (ACTT) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and compassionate use study have shown promise for remdesivir, leading to emergency authorization by the Food and Drug Administration (FDA) for treatment of hospitalized COVID-19 patients. However, several randomized studies have now shown no benefit or increased adverse events associated with remdesivir treatment. Drug development is a time-intensive process and requires extensive safety and efficacy evaluations. In contrast, drug repurposing is a time-saving and cost-effective drug discovery strategy geared towards using existing drugs instead of de novo drug discovery. Treatments for cancer and COVID-19 often have similar goals of controlling inflammation, inhibiting cell division, and modulating the host microenvironment to control the disease. In this review, we focus on anti-cancer drugs that can potentially be repurposed for COVID-19 and are currently being tested in clinical trials.
Identifiants
pubmed: 33239864
doi: 10.2147/DDDT.S282252
pii: 282252
pmc: PMC7680713
doi:
Substances chimiques
Antineoplastic Agents
0
Antiviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5045-5058Subventions
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007337
Pays : United States
Informations de copyright
© 2020 Borcherding et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Nat Rev Immunol. 2008 Jul;8(7):559-68
pubmed: 18575461
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219
pubmed: 32391667
EClinicalMedicine. 2020 Jun 20;24:100418
pubmed: 32766537
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Pharm World Sci. 2005 Dec;27(6):423-31
pubmed: 16341948
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
BMJ. 2020 May 14;369:m1849
pubmed: 32409561
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Cancer Treat Rev. 2012 Nov;38(7):904-10
pubmed: 22651903
JAMA. 2020 Sep 15;324(11):1048-1057
pubmed: 32821939
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):283-287
pubmed: 32283499
Autoimmun Rev. 2020 Jul;19(7):102568
pubmed: 32376398
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
N Engl J Med. 2019 Apr 25;380(17):1597-1605
pubmed: 30969503
Transl Res. 2017 Oct;188:67-79
pubmed: 27931982
Lancet. 1999 May 15;353(9165):1689-94
pubmed: 10335805
Future Oncol. 2015;11(3):409-20
pubmed: 25478720
J Exp Med. 1993 Jun 1;177(6):1675-80
pubmed: 8496685
J Clin Invest. 1998 Feb 15;101(4):746-54
pubmed: 9466968
J Infect. 2020 Jul;81(1):e13-e20
pubmed: 32283144
JAKSTAT. 2012 Jul 1;1(3):159-67
pubmed: 24058765
Nat Rev Clin Oncol. 2015 Dec;12(12):732-42
pubmed: 26483297
Oncologist. 2018 Aug;23(8):943-947
pubmed: 29622697
Leukemia. 2020 Jul;34(7):1805-1815
pubmed: 32518419
J Thromb Haemost. 2020 Jul;18(7):1747-1751
pubmed: 32302448
Blood. 2020 May 21;135(21):1912-1915
pubmed: 32302379
J Med Virol. 2020 Jul;92(7):814-818
pubmed: 32253759
J Exp Med. 1998 Jun 1;187(11):1885-92
pubmed: 9607928
N Engl J Med. 2020 Aug 6;383(6):517-525
pubmed: 32492293
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Infect Dis. 2003 Mar 15;187(6):946-55
pubmed: 12660941
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
JAMA. 2020 May 19;323(19):1897-1898
pubmed: 32208486
J Infect. 2020 Oct;81(4):647-679
pubmed: 32592703
J Virol. 2016 Sep 12;90(19):8924-33
pubmed: 27466418
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
CNS Drugs. 2005;19(2):105-23
pubmed: 15697325
Immunotherapy. 2016 Jul;8(8):959-70
pubmed: 27381687
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
Drugs. 2014 Oct;74(16):1891-1925
pubmed: 25315029
Br J Haematol. 2005 Jan;128(2):192-203
pubmed: 15638853
Front Microbiol. 2017 Jun 28;8:1171
pubmed: 28702009
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Blood. 2001 Jul 1;98(1):210-6
pubmed: 11418482
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
Nat Med. 2016 Jul;22(7):735-43
pubmed: 27294876
Lancet Infect Dis. 2020 Apr;20(4):400-402
pubmed: 32113509
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
J Mol Biol. 2018 Jul 6;430(14):2014-2029
pubmed: 29800567
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370
pubmed: 32205092
N Engl J Med. 2016 Jan 28;374(4):323-32
pubmed: 26641137
Clin Exp Immunol. 2014 Feb;175(2):208-14
pubmed: 24665995
Immunotherapy. 2020 Apr;12(5):269-273
pubmed: 32212881
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
N Engl J Med. 2002 Feb 28;346(9):683-93
pubmed: 11870247
Cancer Cell. 2016 Apr 11;29(4):587-601
pubmed: 27070705
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
N Engl J Med. 2019 Aug 22;381(8):727-738
pubmed: 31433920
PLoS Pathog. 2012 Jan;8(1):e1002352
pubmed: 22241987
J Transl Med. 2020 Apr 14;18(1):164
pubmed: 32290839
Natl Sci Rev. 2020 Jun;7(6):998-1002
pubmed: 34676125
Blood Adv. 2020 Apr 14;4(7):1307-1310
pubmed: 32243501
Leukemia. 2019 Nov;33(11):2695-2709
pubmed: 30988378
Intensive Care Med. 2020 Jun;46(6):1124-1126
pubmed: 32328726
J Infect Dis. 2010 May 15;201(10):1481-7
pubmed: 20377413
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Clin Transl Med. 2020 Jun;10(2):e35
pubmed: 32508009
Circulation. 2020 Jul 14;142(2):184-186
pubmed: 32330083
Antimicrob Agents Chemother. 2014;58(4):1977-86
pubmed: 24419350